JPRN-jRCT2080224028已完成1 期
Open-label, uncontrolled, dose-escalation study of ONO-7475 given as monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors (ONO-7475-02)
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 84 人开始时间: 2018年8月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
- •2. ECOG Performance Status 0-1
- •3. Patients with life expectancy of at least 3 months
排除标准
- •1. Patients with history of serious allergy
- •2. Patients with multiple cancers
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioCTIS2024-513938-38-00Immunocore Limited30
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioEUCTR2021-002008-11-ESImmunocore Limited53
招募中
2 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection2024-513938-38-00Immunocore Limited20
进行中（未招募）
1 期
A study conducted without a control (placebo or other drug) with the aim to establish the maximum tolerated dose of IMP in patient with grass pollen allergic rhinoconjunctivitisGraminacee pollen induced allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001738Term: AllergySystem Organ Class: 100000004870EUCTR2018-004472-35-ITofarma S.p.A.30
进行中（未招募）
1 期
An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000327-27-Outside-EU/EEAIonis Pharmaceuticals, Inc.34